Nature Communications · 2024 · 18 citations · 43 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationCd4 Positive T CellsCd4 T Cell ActivationCd40l SignalingCheckpoint Inhibitor CombinationsImmune Checkpoint Blockade CombinationsImmune Checkpoint Inhibitor TherapyPd-l1 BlockadeT Cell Checkpoint Inhibition
The combination of radiotherapy/chemoradiotherapy and immune checkpoint blockade can result in poor outcomes in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Here, we show that combining ATR inhibition (ATRi) with radiotherapy (RT) increases the frequency of activated NKG2A+PD-1+ T cells in animal models of HNSCC. Compared with the ATRi/RT treatment regimen alone, the addition of simultaneous NKG2A and PD-L1 blockade to ATRi/RT, in the adjuvant, post-radiotherapy setting induces a robust antitumour response driven by higher infiltration and activation of cytotoxic T cells in the tumour microenvironment. The efficacy of this combination relies on CD40/CD40L costimulation and infiltration of activated, proliferating memory CD8+ and CD4+ T cells with persistent or new T cell receptor (TCR) signalling, respectively. We also observe increased richness in the TCR repertoire and emergence of numerous and large TCR clonotypes that cluster based on antigen specificity in response to NKG2A/PD-L1/ATRi/RT. Collectively, our data point towards potential combination approaches for the treatment of HNSCC. Immune checkpoint blockade can result in good outcomes in patients with metastatic head and neck squamous cell carcinoma (HNSCC), but not those with locally advanced disease. Here, the authors demonstrate that the addition of anti-NKG2A and anti-PD-L1 blockade to ATR inhibition and radiotherapy in the adjuvant setting can induce a robust antitumour immune response in mice.
43
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text
Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +11
Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology · 2019 · 1.7K citations
Medicine, Oncology, Pharmacology +12
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti, Nils-Petter Rudqvist, Encouse B. Golden et al. · Nature Medicine · 2018 · 932 citations · Full text